Vaccine

IFPMA IDAP whitepaper: end-to-end access pathway for innovative medicines and vaccines

This IFPMA whitepaper presents the Innovation Development and Access Pathway (IDAP) as a holistic, end-to-end view of how innovative medicines and vaccines move from laboratory research to patient access. It emphasizes that timely access depends on aligned action across R&D, regulation, listing and reimbursement, and health service delivery.

BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial

BioNTech and Genentech have dosed the first patient in the Phase 1 pancreatic cancer mRNA vaccine trial of autogene cevumeran. Earlier Nature data showed immune responses in 8 of 16 patients and established the study as the first mRNA vaccine trial in pancreatic cancer.

Eli Lilly pipeline and deals: GLP-1, vaccines, and 2026 outlook

Eli Lilly’s pipeline and deal strategy are increasingly defined by GLP-1 leadership, obesity and diabetes demand, and a widening push into vaccines. This plan centers the deal and clinical signals BD teams, investors, and executives need to assess what changed and what to watch next.

Amish Health Beliefs: Vaccines, Costs, and Pharma Strategy Insights

This article analyzes Amish health behaviors, including low vaccination rates and selective medical care use, and their implications for pharmaceutical strategy and public health engagement.

STAT+: RFK Jr.’s second year: Vacancies, not vaccines

RFK Jr.’s second year at HHS has been defined by leadership vacancies and policy shifts at the NIH, not vaccine debates. For pharma BD and strategy teams, the key signal is the implementation of Schedule F, which could reshape federal hiring and grant oversight.

STAT+ Pharmalittle: Lilly's 340B Hospital Threat, Ebola Vaccine Funding, and More

STAT+ Pharmalittle reports on Eli Lilly's ultimatum to 340B hospitals regarding claims data submission and the latest developments in Ebola vaccine funding. This news roundup highlights critical shifts in pharmaceutical access and global health initiatives.

Personalized mRNA Cancer Vaccines: A New Era for Melanoma Treatment

Personalized mRNA cancer vaccines are emerging as a powerful new weapon against melanoma, leveraging individual patient tumor data to create tailored treatments. This innovative approach, building on the success of mRNA technology, shows significant promise in preventing cancer recurrence and offers new hope for patients.

Trump's Executive Order on Childhood Vaccine Schedules: Impact on Pharmaceutical Companies

President Trump has signed an executive order initiating an overhaul of the childhood vaccine schedule, signaling potential shifts in public health policy. This move could have significant implications for pharmaceutical companies involved in vaccine development and manufacturing.